EP2297341A4 - Verfahren und zusammensetzungen zur behandlung von morbus huntington - Google Patents

Verfahren und zusammensetzungen zur behandlung von morbus huntington

Info

Publication number
EP2297341A4
EP2297341A4 EP09741640A EP09741640A EP2297341A4 EP 2297341 A4 EP2297341 A4 EP 2297341A4 EP 09741640 A EP09741640 A EP 09741640A EP 09741640 A EP09741640 A EP 09741640A EP 2297341 A4 EP2297341 A4 EP 2297341A4
Authority
EP
European Patent Office
Prior art keywords
huntington
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09741640A
Other languages
English (en)
French (fr)
Other versions
EP2297341A1 (de
Inventor
Michael Hayden
Jeffrey Carroll
Simon Warby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of EP2297341A1 publication Critical patent/EP2297341A1/de
Publication of EP2297341A4 publication Critical patent/EP2297341A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
EP09741640A 2008-05-09 2009-05-08 Verfahren und zusammensetzungen zur behandlung von morbus huntington Withdrawn EP2297341A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71465208P 2008-05-09 2008-05-09
PCT/CA2009/000645 WO2009135322A1 (en) 2008-05-09 2009-05-08 Methods and compositions for the treatment of huntington's disease

Publications (2)

Publication Number Publication Date
EP2297341A1 EP2297341A1 (de) 2011-03-23
EP2297341A4 true EP2297341A4 (de) 2013-01-09

Family

ID=41264389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09741640A Withdrawn EP2297341A4 (de) 2008-05-09 2009-05-08 Verfahren und zusammensetzungen zur behandlung von morbus huntington

Country Status (4)

Country Link
EP (1) EP2297341A4 (de)
AU (1) AU2009244013B2 (de)
CA (1) CA2726866A1 (de)
WO (1) WO2009135322A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054725A2 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
ES2733708T3 (es) 2010-02-08 2019-12-02 Ionis Pharmaceuticals Inc Reducción selectiva de variantes alélicas
EP2534262B1 (de) 2010-02-08 2016-12-14 Ionis Pharmaceuticals, Inc. Selektive reduktion von allelvarianten
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
US20150051389A1 (en) 2011-08-11 2015-02-19 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
EP2906256B1 (de) 2012-10-12 2018-08-22 Ionis Pharmaceuticals, Inc. Selektive antisense-verbindungen und verwendungen davon
CA2899924A1 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45270A (fr) * 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP4069846A1 (de) * 2019-12-07 2022-10-12 Scribe Therapeutics Inc. Zusammensetzungen und verfahren für htt-targeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187931A1 (en) * 2000-04-13 2002-12-12 Michael Hayden Modulating cell survival by modulating huntingtin function
US20100299768A1 (en) * 2007-06-18 2010-11-25 Commissariat A L'energie Atomique Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005562A2 (en) * 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
ATE522626T1 (de) * 2005-06-28 2011-09-15 Medtronic Inc Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
US9273356B2 (en) * 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187931A1 (en) * 2000-04-13 2002-12-12 Michael Hayden Modulating cell survival by modulating huntingtin function
US20100299768A1 (en) * 2007-06-18 2010-11-25 Commissariat A L'energie Atomique Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENOVAN-WRIGHT E M ET AL: "RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 13, no. 6, 1 March 2006 (2006-03-01), pages 525 - 531, XP002452333, ISSN: 0969-7128 *
See also references of WO2009135322A1 *

Also Published As

Publication number Publication date
EP2297341A1 (de) 2011-03-23
AU2009244013A1 (en) 2009-11-12
WO2009135322A1 (en) 2009-11-12
AU2009244013B2 (en) 2015-06-25
CA2726866A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
EP2297341A4 (de) Verfahren und zusammensetzungen zur behandlung von morbus huntington
HK1225970A1 (zh) 利用拉喹莫德治療亨廷頓氏病
IL246293B (en) New preparations and methods for the treatment of vaccine-related diseases
HK1212598A1 (zh) 用於預防口腔疾病的組合物及方法
EP2212440A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
EP2120580A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP2125855A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und anderen krankheiten
EP2152318A4 (de) Anwendungen und zusammensetzungen zur behandlung von schuppenflechten und morbus crohn
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
EP2046993A4 (de) Rna-interferenzzusammensetzungen und verfahren zur behandlung von morbus huntington
HK1145141A1 (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
EP2217238A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie
HK1245679A1 (zh) 用於治療皮膚疾病和病症的方法和組合物
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2271352A4 (de) Zusammensetzungen und verfahren zur behandlung von neoplastischen erkrankungen
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2320939A4 (de) Gewebe-kallikrein zur behandlung der parkinson-krankheit
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2421554A4 (de) Gewebe-kallikrein zur behandlung von morbus huntington
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2142566A4 (de) Verfahren und zusammensetzungen zur behandlung von proliferativen krankheiten
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154911

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20121211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/14 20060101ALI20121205BHEP

Ipc: A61K 31/713 20060101ALI20121205BHEP

Ipc: C12Q 1/68 20060101AFI20121205BHEP

Ipc: A61K 31/7088 20060101ALI20121205BHEP

Ipc: C12N 15/85 20060101ALI20121205BHEP

Ipc: G01N 33/53 20060101ALI20121205BHEP

Ipc: C07H 21/00 20060101ALI20121205BHEP

Ipc: C12N 15/63 20060101ALI20121205BHEP

Ipc: C12N 15/11 20060101ALI20121205BHEP

Ipc: G01N 33/68 20060101ALI20121205BHEP

17Q First examination report despatched

Effective date: 20150511

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170523

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154911

Country of ref document: HK